他汀治疗患者富含甘油三酯脂蛋白胆固醇与心血管事件风险:TNT试验分析
TNT试验事后分析评估接受他汀治疗的冠心病患者中富含甘油三酯脂蛋白胆固醇(TRL-C)与心血管风险的关系。结果显示基线TRL-C较高者5年主要不良心血管事件(MACE)率更高,阿托伐他汀80mg/d相较10mg/d在高TRL-C五分位组显著降低MACE风险,且TRL-C降低与MACE风险降低独立相关。
要点
- 在接受阿托伐他汀10mg/d的冠心病患者中,基线TRL-C最高五分位组5年MACE率显著高于最低五分位组。
- 阿托伐他汀80mg/d相较10mg/d在基线TRL-C第3-5五分位组显著降低MACE风险,相对风险降低29%-41%。
- 他汀治疗中TRL-C的降低与MACE风险降低独立相关,且幅度与LDL-C降低相似。
核心结论
- 在TNT试验的事后分析中,接受他汀治疗的冠心病患者基线TRL-C升高与心血管风险增加相关,且高TRL-C患者从他汀强化降脂中获益更明显。
研究设计与样本
- TNT试验为随机对照研究,冠心病且LDL-C 130-250 mg/dL患者经阿托伐他汀10mg/d 8周导入期后,LDL-C<130 mg/dL者随机接受阿托伐他汀10mg/d(n=5006)或80mg/d(n=4995)。
- TRL-C计算为总胆固醇减去高密度脂蛋白胆固醇减去LDL-C,主要终点为冠心病死亡、非致死性心肌梗死、复苏性心脏骤停或卒中(MACE)。
主要发现
- 阿托伐他汀10mg/d使TRL-C从初始33.9±16.6 mg/dL降低10.7%,阿托伐他汀80mg/d额外降低15.4%。
- 接受阿托伐他汀10mg/d者中,基线TRL-C最高五分位组(Q5)5年MACE率为13.8%,最低五分位组(Q1)为9.7%,Q5 vs Q1风险比1.48(95%CI 1.15-1.92),P-trend<0.0001。
- 阿托伐他汀80mg/d vs 10mg/d在Q1-Q2未显著改变MACE风险,但在Q3-Q5显著降低风险(相对风险降低29%-41%,均P<0.0250),效应修饰P=0.0053。
- 调整分析中,TRL-C每降低1个标准差百分比,MACE风险显著降低(HR 0.93,95%CI 0.86-1.00,P=0.0482),独立于LDL-C降低,幅度与LDL-C每降低1个标准差(HR 0.89,95%CI 0.83-0.95,P=0.0008)相似。
临床怎么用
- 对接受他汀治疗的冠心病患者,可关注TRL-C水平以识别残余心血管风险较高的患者。
- 基线TRL-C较高的冠心病患者可能从他汀强化治疗中获得更显著的MACE风险降低。
局限性
- 本研究为TNT试验的事后分析(post hoc analysis)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mendelian randomization data suggest that the genetic determinants of lifetime higher triglyceride-rich lipoprotein-cholesterol (TRL-C) are causally related to cardiovascular disease and therefore a potential therapeutic target. The relevance of TRL-C among patients receiving statins is unknown. We assessed the relationship between TRL-C and cardiovascular risk, and whether this risk was modifiable among patients receiving statins in the TNT trial (Treating to New Targets). METHODS: Patients with coronary heart disease and low-density lipoprotein cholesterol (LDL-C) 130 to 250 mg/dL entered an 8-week run-in phase with atorvastatin 10 mg/d (ATV10). After this period, participants with LDL-C <130 mg/dL entered the randomized phase with ATV10 (n=5006) versus atorvastatin 80 mg/d (ATV80, n=4995). The primary end point was coronary heart disease death, nonfatal myocardial infarction, resuscitated cardiac arrest, or stroke (major adverse cardiovascular events [MACE]). TRL-C was calculated as total cholesterol minus high-density lipoprotein cholesterol minus LDL-C. The effect of atorvastatin on TRL-C was assessed during the run-in phase (ATV10) and randomized phase (ATV80 versus ATV10). The risk of MACE was assessed across quintiles (Q) of baseline TRL-C (and, for comparison, by baseline triglycerides and non-high-density lipoprotein cholesterol) during the randomized period. Last, the association between TRL-C changes with atorvastatin and cardiovascular risk was assessed by multivariate Cox regression. RESULTS: ATV10 reduced TRL-C 10.7% from an initial TRL-C of 33.9±16.6 mg/dL. ATV80 led to an additional 15.4% reduction. Cardiovascular risk factors positively correlated with TRL-C. Among patients receiving ATV10, higher TRL-C was associated with higher 5-year MACE rates (Q1=9.7%, Q5=13.8%; hazard ratio Q5-versus-Q1, 1.48; 95% confidence interval, 1.15-1.92; P-trend<0.0001). ATV80 (versus ATV10) did not significantly alter the risk of MACE in Q1-Q2, but significantly reduced risk in Q3-Q5 (relative risk reduction, 29%-41%; all P<0.0250), with evidence of effect modification ( P-homogeneity=0.0053); results were consistent for triglycerides ( P-homogeneity=0.0101) and directionally similar for non-high-density lipoprotein cholesterol ( P-homogeneity=0.1387). Last, in adjusted analyses, a 1 SD percentage reduction in TRL-C with atorvastatin resulted in a significant lower risk of MACE (hazard ratio, 0.93; 95% confidence interval, 0.86-1.00; P=0.0482) independent of the reduction in LDL-C and of similar magnitude to that per 1 SD lowering in LDL-C (hazard ratio, 0.89; 95% confidence interval, 0.83-0.95; P=0.0008). CONCLUSIONS: The present post hoc analysis from TNT shows that increased TRL-C levels are associated with an increased cardiovascular risk and provides evidence for the cardiovascular benefit of lipid lowering with statins among patients who have coronary heart disease with high TRL-C. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00327691.
引用
- Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, et al. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. Circulation. 2018. PMID: 29618599. doi:10.1161/CIRCULATIONAHA.117.032318
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。